Sabin Vaccine Institute Receives $10M Grant to Raise Confidence in Vaccines

WASHINGTON, D.C – The Sabin Vaccine Institute (Sabin) today announced it has received a three-year grant valued at $10.4 million to strengthen vaccine acceptance. In 2019, the World Health Organization identified vaccine hesitancy – the reluctance or refusal to vaccinate despite the availability of vaccines – as one of the top 10 threats to global health.

Sabin Vaccine Institute Strengthens Ebola Sudan and Marburg Vaccines Program with Additional NIAID Partnership

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced that it has partnered with the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), to manufacture prototype ChAd3 vectored Ebola Sudan and Marburg vaccines to be used for further clinical evaluation and outbreak preparedness and to potentially protect military, first responders, health care and laboratory workers, and other at-risk populations.

One Step Closer to a World Without Polio – Type 3 Polio Eradicated – A Statement by the Sabin Vaccine Institute

WASHINGTON, DC – Today, we are one step closer to a world without polio. The Sabin Vaccine Institute, founded in memory of oral polio vaccine creator Dr. Albert Sabin, applauds the tremendous achievement by the global polio community in eradicating wild poliovirus type 3.

Pages